Viridian Therapeutics, Inc.\DE (VRDN) Liabilities and Shareholders Equity (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted Liabilities and Shareholders Equity of $1.1 billion for Q2 2026, up 88.4% from $582.32 million a year earlier and up 39.1% from the prior quarter.
Powered by 
Analysis
Viridian Therapeutics, Inc.\DE (VRDN) Liabilities and Shareholders Equity (2013 - 2026) Analysis & Trends
At the end of FY2025, Viridian Therapeutics, Inc.\DE's Liabilities and Shareholders Equity came in at $899.42 million, up 21.1% from FY2024.
- Annual Liabilities and Shareholders Equity has increased for six consecutive years, with a five-year compound annual growth rate of 46.9% (FY2020 to FY2025).
- In prior years, Viridian Therapeutics, Inc.\DE's Liabilities and Shareholders Equity was $742.4 million in FY2024 (+51.4%), $490.42 million in FY2023 (+12.7%), $435.09 million in FY2022 (+113.6%) and $203.71 million in FY2021 (+55.2%).
- The Q2 2026 figure stands as the highest quarterly Liabilities and Shareholders Equity in data going back to Q4 2013.
- On a year-over-year basis, Liabilities and Shareholders Equity has increased in each of the last three quarters, with growth averaging 36.8% over the last eight quarters.
- The strongest year-over-year quarter for Liabilities and Shareholders Equity in the past five years was Q3 2021, with growth of 573.7%; the weakest was Q3 2023, with a decline of 25.4%.
- According to Business Quant data, Liabilities and Shareholders Equity for the three prior quarters was $789.02 million (Q1 2026), $899.42 million (Q4 2025) and $577.14 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,082.65 Bn | 1,051.23 Bn | 19.71 Bn | 142.28 Bn |
| 2 | Johnson & Johnson | 623.68 Bn | 542.21 Bn | 17.26 Bn | 201.06 Bn |
| 3 | AbbVie | 459.43 Bn | 432.59 Bn | 12.70 Bn | 135.12 Bn |
| 4 | Merck | 354.80 Bn | 309.23 Bn | 12.21 Bn | 129.80 Bn |
| 5 | Novartis Ag | 269.16 Bn | 225.03 Bn | 11.24 Bn | 122.03 Bn |
| 6 | Astrazeneca | 244.40 Bn | 217.97 Bn | 12.86 Bn | 115.83 Bn |
| 7 | Amgen | 220.17 Bn | 175.57 Bn | 7.24 Bn | 95.64 Bn |
| 8 | Gilead Sciences | 183.05 Bn | 157.16 Bn | 6.22 Bn | 49.36 Bn |
| 9 | Pfizer | 160.27 Bn | 107.22 Bn | 10.94 Bn | 201.13 Bn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.15 Bn | 2.15 Bn | - | 1.10 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.10 Bn |
| Mar 31, 2026 | 789.02 Mn |
| Dec 31, 2025 | 899.42 Mn |
| Sep 30, 2025 | 577.14 Mn |
| Jun 30, 2025 | 582.32 Mn |
| Mar 31, 2025 | 660.98 Mn |
| Dec 31, 2024 | 742.40 Mn |
| Sep 30, 2024 | 771.90 Mn |
| Jun 30, 2024 | 585.66 Mn |
| Mar 31, 2024 | 630.38 Mn |
| Dec 31, 2023 | 490.42 Mn |
| Sep 30, 2023 | 328.76 Mn |
| Jun 30, 2023 | 351.47 Mn |
| Mar 31, 2023 | 386.64 Mn |
| Dec 31, 2022 | 435.09 Mn |
| Sep 30, 2022 | 440.58 Mn |
| Jun 30, 2022 | 169.81 Mn |
| Mar 31, 2022 | 183.17 Mn |
| Dec 31, 2021 | 203.71 Mn |
| Sep 30, 2021 | 221.21 Mn |
API Access
Viridian Therapeutics, Inc.\DE Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=VRDN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "VRDN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=VRDN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();